Compositions of omega 3 fatty acids to treat diseases which involve damage to the nervous system

a technology of nervous system damage and which is applied in the field of omega 3 fatty acids to treat diseases involving damage to the nervous system, can solve the problems of corneal and conjunctival damage, no current treatment for these eye pathologies, and no treatment to limit axonal injury and improve neuronal function in these patients, so as to reduce morbidity

Inactive Publication Date: 2016-11-17
GEORGIOU TASSOS
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0045]The compositions described in this patent represents a novel therapeutic approach to reduce morbidity resulting from diseases which involve damage to the nervous system, and particularly for use in treatment of 2nd cranial (optic) ne

Problems solved by technology

Voluntary eye closure may not be possible and can result in damage to the cornea and conjunctiva.
There is no current treatment for these eye pathologies.
Currently there is no treatment to limit axonal injury and improve neuronal function in these patients.
Optic Nerve Damage Due to Glaucoma
This results in inflammatory response and damage to retinal ganglion cells by vascular dysregulation resulting in periods of ischaemia and reperfusion damage.
There is a higher risk of field loss among patients who have larger intraocular pressure swings at different times of the day.
Late diagnosis or advanced visual field loss a

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions of omega 3 fatty acids to treat diseases which involve damage to the nervous system
  • Compositions of omega 3 fatty acids to treat diseases which involve damage to the nervous system
  • Compositions of omega 3 fatty acids to treat diseases which involve damage to the nervous system

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0140]Method and Materials : A pilot study of 10 eyes with advanced optic nerve damage due to glaucoma. All eyes had reduced visual acuity and reduced field test. They were treated with omega 3 which consisted of purified ethyl esters rich in EPA (400 mg) and DHA (200 mg) per gram for the liquid formulation. The dosage used in this pilot study was 15 ml to 20 ml of liquid formulation providing approximately 5.1 g to 6.8 g of EPA and 2.4 g to 3.2 g of DHA per day. The dosage was divided into two daily doses of 7.5 to 10 ml each. The dose was adjusted so that the blood AA / EPA ratio was within 1 to 1.5. The intraocular pressures an all eyes were well controlled with anti-glaucomatous drops.

[0141]Study 1 Results : The visual acuity was recorded using the EDTRS electronic chart at 6 weeks and 3 months. Visual field testing was also recorded with a field testing machine (Zeiss, Humphreys).

[0142]FIG. 1 shows the number of lines gained and the number of eyes over the study period. There is ...

example 2

[0146]Method and Materials: A pilot study of 10 eyes with optic nerve damage due to ischaemia, inflammation and post trauma. These patients had a minimum of 6 months post optic nerve damage before starting on our treatment. They were treated with omega 3 which consisted of purified ethyl esters rich in EPA (400 mg) and DHA (200 mg) per gram for the liquid formulation. The dosage used in this pilot study was 15 ml to 20 ml of liquid formulation providing approximately 5.1 g to 6.8 g of EPA and 2.4 g to 3.2 g of DHA per day. The dosage was divided into two daily doses of 7.5 to 10 ml each. The dose was adjusted so that the blood AA / EPA ratio was within 1 to 1.5.

[0147]Study 2 Results: The visual acuity was recorded using the EDTRS electronic chart at 6 weeks 3 months and 4.5 months.

[0148]FIG. 4 shows the number of lines gained and the number of eyes over the period of 4.5 months. There is an increase of 1.6 lines of visual acuity at 6 weeks, 2.4 lines at 3 months and 2.5 lines at 4.5 m...

example 3

[0153]Two patients with scleritis who are only controlled with 10 mg of prednisolone had to stop due to the side effects of the steroid. In both cases, using the invention of 8 g per day of EPA and DHA were used to control their symptoms over at least 1 year follow up.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Massaaaaaaaaaa
Massaaaaaaaaaa
Massaaaaaaaaaa
Login to view more

Abstract

Compositions comprising omega 3 fatty acids for use in the treatment, amelioration or prevention of various conditions, disorders, and diseases which involve damage to the nervous system, as the peripheral nervous system neuropathy and glaucoma.

Description

TECHNICAL FIELD OF THE INVENTION[0001]The present invention relates generally to the fields of medicine, foods, and health food supplements. More particularly, it relates to compositions comprising omega 3 fatty acids for use in the treatment of a disease, and in particular to compositions comprising eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) for use in the treatment, amelioration or prevention of various conditions, disorders, and diseases which involve damage to the nervous system, as the peripheral nervous system neuropathy and glaucoma.BACKGROUND OF THE INVENTION[0002]Neuropathy is damage or disease involving nerves, which may affect sensation, movement, gland or organ function and other aspects of health, depending on the type of nerve affected. Common causes include systemic diseases (such as diabetes or leprosy), vitamin deficiency, medication (e.g., chemotherapy), traumatic injury, excessive alcohol consumption, immune system disease or infection, or it may b...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/202A23L33/12
CPCA61K31/202A23V2002/00A23L33/12A61P25/00A61P25/02A61P27/02A61P27/06A61P43/00A61P9/10A61K2300/00A23V2200/08A23V2200/322A23V2250/1868A23V2250/187
Inventor GEORGIOU, TASSOS
Owner GEORGIOU TASSOS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap